Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.

Clinical Trials Cardiovascular Companies

Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation

As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.

Deals Companies Business Strategies

Biological E Taps Takeda Tech For Affordable Combo Vaccines

Takeda is to transfer selected vaccine technologies to an Indian manufacturer to enable the production of affordable combination vaccines for lower income countries, although likely volumes and prices remain unclear for now.

Vaccines Manufacturing Infectious Diseases

Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

Leadership Financing Strategy
Advertisement


 Recent Tweets from Scrip


Commercial Explore this Topic

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.

Deals M & A Business Strategies

Bio Boost For Benelux As BioGeneration Ventures Beats Fund Target

Dutch life sciences venture capital firm BioGeneration Ventures has exceeded the €50m target in a third closing of its BGV III fund, raising €66m. It intends to focus its investments on firms in the Netherlands, Belgium, Luxembourg and Germany, and expects to secure further funds, reaching the maximum fund size of €75m by the end of 2017.

Financing StartUps and SMEs Netherlands

Latest From Commercial

Mehta Analysis: Shaming Biopharma Managers

Shame has historically been used as an effective tool in bringing about a change in pricing policy within an industry. But could it be wielded against the pharma industry today? Viren Mehta, founding partner of Mehta Partners, LLC, considers.

Pricing Debate United States

What Now For Lonely Stada? Bain & Civen Takeover Bid Collapses

In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Civen; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.

Generic Drugs Deals

ImCheck Therapeutics Pursues Immuno-Oncology Antibodies

Emerging Company Profile: The new anticancer antibody developer ImCheck Therapeutics has set up in Marseille, France, a location that is becoming increasingly attractive to biotech start-ups that could rival more established areas in coming years.

ImmunoOncology StartUps and SMEs

Podcast: Scaling Up Your Business

BIO International 2017 discussion: growing a biotech business. Informa's global content editor Mike Ward discusses how to scale up your SME and access international markets with experts in the field. This content was produced by Scrip alongside a sponsored project with MSP, a provider of specialized science campuses in Manchester and Cheshire, UK.

Business Strategies StartUps and SMEs

Obituary: Lupin’s founder Desh Bandhu Gupta And His People Mantra

Lupin’s founder and chairman, Desh Bandhu Gupta, who died aged 79 on June 26, was known to give employees significant autonomy at the workplace, with some saying that people were the crux of his company-building mantra.

India Commercial

Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market

Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.

Approvals Launches

Policy & Regulation Explore this Topic

Kamada's Plans For Emphysema Drug Delayed By Years After MAA Withdrawal

Kamada has withdrawn its European approval application for an inhaled version of its emphysema drug Glassia – a move that shocked investors because of the company's continued insistence data from a failed pivotal study would be enough to convince regulators.

Market Intelligence Respiratory Research and Development Strategies

Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market

Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.

Approvals Launches

This Means War: Identical Labels Recommended For Gilead, AbbVie's HCV Drugs In Europe

AbbVie and Gilead have won positive recommendations in Europe and matching eight-week dosing labels for their latest hepatitis C combination therapies, Maviret and Vosevi – now it's all about the price.

Approvals Infectious Diseases

EU CHMP OKs Imraldi, Samsung Bioepis’ Biosimilar Of AbbVie’s Humira

The EU’s CHMP has given the green light to Imraldi, Samsung Bioepis’ biosimilar version of AbbVie’s blockbuster adalimumab product Humira. If approved by the European Commission, this will be the South Korean company’s third biosimilar anti-TNF alpha product to gain a marketing authorization in the EU.

Approvals Europe

Research & Development Explore this Topic

Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards

Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.

Blood & Coagulation Disorders Research and Development Strategies Clinical Trials

Latest From Research & Development

ConSynance Differentiates NASH Asset To Charm China

Dr. Shuang Liu, president and co-founder of ConSynance Therapeutics, talks with Scrip’s Brian Yang about the US-based startup's plans to develop and commercialize in China its assets for indications including NASH.

China Research & Development

Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90

Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.

Platform Technologies Cancer

Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study

Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.

Clinical Trials Companies
UsernamePublicRestriction

Register

Advertisement